Apria Announces Financial Results for Fourth Quarter and Full Year 2021

Rhea-AI Summary

Apria reported its fourth quarter and full year 2021 financial results, highlighting a 4Q net revenue of $296.5 million, a 0.9% increase year-over-year, despite challenges including a major product recall and supply chain disruptions. Net income decreased by 34.5% to $17.0 million. Adjusted EBITDA for the quarter was $58.4 million, down 8.8%. For the full year, net revenue rose 3.3% to $1,145.3 million, with net income increasing by 40.6% to $64.9 million. Despite issues, the company expects strong demand for CPAP and ventilation products to continue.

Positive

• Full year net revenue increased by 3.3% to $1,145.3 million.
• Full year net income rose by 40.6% to $64.9 million.
• Continued strong demand for CPAP and ventilation products.

Negative

• 4Q net income declined by 34.5% to $17.0 million.
• 4Q Adjusted EBITDA dropped by 8.8% to $58.4 million.
• Supply chain disruptions and Philips recall impacted new patient starts.

INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the “Company” or “Apria”) (Nasdaq: APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results.

“We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth quarter revenue and Adjusted EBITDA were at the high end of our guidance ranges, while Adjusted EBITDA less Patient Equipment Capex was in-line with our expectations,” said Dan Starck, CEO of Apria. “During the fourth quarter, we continued to be impacted by the Philips recall and the supply chain disruption which slowed new sleep patient starts and new ventilation patient starts in the quarter. That said, we continue to see strong demand for CPAP and ventilation, and we expect demand will remain strong for the foreseeable future.  Overall, 2021 was a banner year for Apria despite the COVID pandemic and supply chain constraints. I am proud of what we accomplished together in 2021 and we remain steadfast in our mission of Improving the Quality of Life for our Patients at Home.”

Fourth Quarter 2021 Financial Highlights

Comparisons are to the three months ended December 31, 2020.

• Net revenue of $296.5 million, up 0.9% compared to $293.8 million
• Net Income of $17.0 million, or $0.44 per diluted share, down 34.5% from $25.9 million
• Adjusted EBITDA of $58.4 million, down 8.8% compared to $64.1 million
• Adjusted EBITDA less Patient Equipment Capex of $28.3 million, down 19.1% from $34.9 million

Full Year 2021 Financial Highlights

Comparisons are to the full year ended December 31, 2020.

• Net revenue of $1,145.3 million, up 3.3% compared to $1,108.7 million
• Net Income of $64.9 million, or $1.66 per diluted share, up 40.6% from $46.1 million
• Adjusted EBITDA of $232.0 million, up 2.3% compared to $226.9 million
• Adjusted EBITDA less Patient Equipment Capex of $136.0 million, up 1.3% from $134.2 million

About Apria

Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 280 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria’s locations are accredited by The Joint Commission.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding Apria, Inc.’s (“Apria”) expectations regarding the proposed acquisition of Apria by Owens & Minor Inc. (the “proposed merger”) and the future performance and financial results of Apria’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Apria cautions readers of this communication that such “forward looking statements”, wherever they occur in this communication or in other statements attributable to Apria, are necessarily estimates reflecting the judgment of Apria’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward looking statements.”

Factors that could cause Apria’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement relating to the proposed merger; the inability to complete the proposed merger due to the failure to obtain approval of Apria’s stockholders for the proposed merger or the failure to satisfy other conditions to completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed merger; risks related to disruption of management’s attention from Apria’s ongoing business operations due to the proposed merger; the effect of the announcement of the proposed merger on Apria’s relationships with its customers, suppliers and other third parties, as well as its operating results and business generally; the risk that the proposed merger will not be consummated in a timely manner; exceeding the expected costs of the merger; risks related to the COVID-19 public health emergency, product and related recalls; the profitability of Apria’s capitation arrangements; renegotiation or termination of Apria’s contracts; reimbursements by payors; our reliance on relatively few vendors; competition in the home healthcare industry; the inherent risk of liability in the provision of healthcare services; and reductions in Medicare and Medicaid and commercial payor reimbursement rates.

Additional factors that could cause Apria’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” sections of Apria’s Annual Report on Form 10-K for the period ended December 31, 2020 and Quarterly Reports on Form 10-Q for the periods ended June 30, 2021 and September 30, 2021, as such factors may be further updated from time to time in Apria’s other filings with the Securities and Exchange Commission (“SEC”) including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which is expected to be filed on or about the date of this press release. These reports are or will be accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in Apria’s filings with the SEC. Apria undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Use of Non-GAAP Financial Information

This press release contains certain financial measures that are not recognized under generally accepted accounting principles in the United States (“GAAP”). The Company uses EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex, which are financial measures that are not prepared in accordance with GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to GAAP measures.

EBITDA is a non-GAAP measure that represents net income for the period before the impact of interest income, interest expense, other income and expense, income taxes, loss from equity method investment, and depreciation and amortization. EBITDA is widely used by securities analysts, investors and other interested parties to evaluate the profitability of companies. EBITDA eliminates potential differences in performance caused by variations in capital structures, tax positions, the cost and age of tangible assets and the extent to which intangible assets are identifiable. Adjusted EBITDA is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business either period-over-period or with other businesses. The Company uses Adjusted EBITDA as a key profitability measure to assess the performance of our business. We believe that Adjusted EBITDA should, therefore, be made available to securities analysts, investors and other interested parties to assist in their assessment of the performance of our business. Adjusted EBITDA less Patient Equipment Capex is a non-GAAP measure that represents Adjusted EBITDA less purchases of patient equipment net of dispositions (“Patient Equipment Capex”). For purposes of this metric, Patient Equipment Capex is measured as the value of the patient equipment received less the net book value of dispositions of patient equipment during the accounting period. This metric is useful in evaluating the financial performance of the Company as the business requires significant capital expenditures to maintain its patient equipment fleet due to asset replacement and contractual commitments. The Company believes that Adjusted EBITDA less Patient Equipment Capex should, therefore, be made available to securities analysts, investors, and other interested parties to assist in their assessment of the performance of our business.

Reconciliations of historical EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex to our net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, are included in the tables attached to this press release. EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex should not be considered alternatives to net income or any other measure of financial performance calculated and presented in accordance with GAAP. EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex may not be comparable to similarly titled measures of other organizations because other organizations may not calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex in the same manner as the Company calculates these measures.

The Company’s uses of EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

• although depreciation and amortization are noncash charges, the assets being depreciated and amortized may have to be replaced in the future. EBITDA and Adjusted EBITDA do not reflect capital expenditure requirements for such replacements or other contractual commitments;
• EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex do not reflect changes in, or cash requirements for, our working capital needs;
• EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex do not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and
• other companies, including companies in our industry, may calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex measures differently, which reduces their usefulness as a comparative measure.

EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex exclude items that can have a significant effect on profit or loss and should, therefore, be used in conjunction with, not as substitutes for, profit or loss for the period. The Company compensates for these limitations by separately monitoring net income for the period.

APRIA, INC.
CONSOLIDATED BALANCE SHEETS (Unaudited)
(In thousands, except share and per share data)
		December 31,				December 31,
		2021				2020
ASSETS
CURRENT ASSETS
Cash and cash equivalents		$	219,561			$	195,197
Accounts receivable			81,720				74,774
Inventories			8,754				6,680
Prepaid expenses and other current assets			23,242				24,003
TOTAL CURRENT ASSETS			333,277				300,654
NONCURRENT RESTRICTED CASH			515				—
PATIENT EQUIPMENT, less accumulated depreciation of $366,126 and $356,888 as of December 31, 2021 and December 31, 2020, respectively			221,534				223,972
PROPERTY, EQUIPMENT AND IMPROVEMENTS, NET			21,281				25,419
INTANGIBLE ASSETS, NET			71,651				61,497
OPERATING LEASE RIGHT-OF-USE ASSETS			71,808				57,869
GOODWILL			28,985				—
EQUITY METHOD INVESTMENT			2,809				—
DEFERRED INCOME TAXES, NET			4,338				18,258
NOTE RECEIVABLE, RELATED PARTY			2,071				—
OTHER ASSETS			17,160				17,315
TOTAL ASSETS		$	775,429			$	704,984
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable		$	133,485			$	116,886
Accrued payroll and related taxes and benefits			52,484				55,628
Other accrued liabilities			32,687				33,513
Deferred revenue			28,296				25,821
Current portion of operating lease liabilities			23,419				23,977
Current portion of long-term debt			36,458				20,833
TOTAL CURRENT LIABILITIES			306,829				276,658
LONG-TERM DEBT, less current portion			341,001				376,389
OPERATING LEASE LIABILITIES, less current portion			48,304				35,358
DEFERRED INCOME TAXES, NET			7,312				—
OTHER NONCURRENT LIABILITIES			32,250				42,924
TOTAL LIABILITIES			735,696				731,329
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $0.01 par value: 100,000,000 authorized; no shares issued as of December 31, 2021 and February 10, 2021
Common stock, $0.01 par value: 1,000,000,000 authorized; 35,521,594 and 35,210,915 shares issued and outstanding as of December 31, 2021 and February 10, 2021, respectively			355				—
Additional paid-in capital			954,933				954,087
Accumulated deficit			(915,555	)			(980,432	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)			39,733				(26,345	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)		$	775,429			$	704,984

APRIA, INC.
CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
(In thousands, except share and per share data)
		Three Months Ended								Year Ended
		December 31,								December 31,
		2021				2020				2021				2020
Net revenues:
Fee-for-service arrangements		$	240,838			$	237,216			$	917,652			$	883,846
Capitation			55,687				56,573				227,623				224,871
TOTAL NET REVENUES			296,525				293,789				1,145,275				1,108,717
Costs and expenses:
Cost of net revenues:
Product and supply costs			53,444				51,104				206,167				192,667
Patient equipment depreciation			25,409				25,479				101,040				101,319
Home respiratory therapists costs			4,134				4,034				16,479				16,882
Other			4,773				3,733				17,602				17,402
TOTAL COST OF NET REVENUES			87,760				84,350				341,288				328,270
Selling, distribution and administrative			183,698				175,189				706,633				709,299
TOTAL COSTS AND EXPENSES			271,458				259,539				1,047,921				1,037,569
OPERATING INCOME			25,067				34,250				97,354				71,148
Interest expense and other			2,899				2,261				11,781				6,308
Interest income and other			(112	)			(46	)			(254	)			(498	)
Gain from derecognition of nonfinancial asset			—				—				(3,994	)			—
INCOME BEFORE INCOME TAXES			22,280				32,035				89,821				65,338
Income tax expense			4,538				6,164				24,153				19,199
Loss from equity method investment			791				—				791				—
NET INCOME		$	16,951			$	25,871			$	64,877			$	46,139
			Three							February 10, 2021
			Months Ended							through
			December 31, 2021							December 31, 2021
Basic and diluted earnings per share:
Net income attributable to common stockholders		$	16,951							$	63,338
Weighted average common shares outstanding:
Basic			35,485,376								35,325,734
Diluted			38,210,148								38,113,601
Net income per common share:
Basic		$	0.48							$	1.79
Diluted		$	0.44							$	1.66

 

_______________________
(1)   Prior to our initial public offering (“IPO” or “offering”), our business was conducted through Apria Healthcare Group LLC (formerly known as Apria Healthcare Group Inc.) which did not have a common capital structure with Apria, Inc. As such, we computed EPS for the period the Company’s common stock was outstanding during 2021, referred to as the Post-IPO period. We have defined the Post-IPO period as February 10, 2021, the effective date of the pre-IPO reorganization, through December 31, 2021.

APRIA, INC.
NET REVENUES FOR EACH CORE SERVICE LINE (unaudited)
		Three Months Ended December 31,						Year Ended December 31,
(in thousands)		2021			2020			2021			2020
Home respiratory therapy		$	118,283		$	118,549		$	467,422		$	453,826
OSA treatment			126,328			123,442			480,245			454,407
NPWT			10,197			12,215			40,455			42,966
Other equipment and services			41,717			39,583			157,153			157,518
Net revenues		$	296,525		$	293,789		$	1,145,275		$	1,108,717

APRIA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
		Year Ended December 31,
(in thousands)		2021				2020
Net cash provided by operating activities		$	211,997			$	196,713
Net cash used in investing activities			(144,208	)			(91,727	)
Net cash (used in) provided by financing activities			(42,910	)			15,520
Net increase in cash and cash equivalents and restricted cash			24,879				120,506
Cash and cash equivalents and restricted cash at beginning of period			195,197				74,691
Cash and cash equivalents and restricted cash at end of period		$	220,076			$	195,197

Non-GAAP Financial Information
This press release presents Apria’s EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex for the three and twelve months ended December 31, 2021 and 2020.

EBITDA is a non-GAAP measure that represents net income for the period before the impact of interest income, interest expense, other income and expense, income taxes, loss from equity method investment, and depreciation and amortization.

Adjusted EBITDA is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business either period-over-period or with other businesses.

Adjusted EBITDA less Patient Equipment Capex is a non-GAAP measure that represents Adjusted EBITDA less purchases of patient equipment net of dispositions (“Patient Equipment Capex”). For purposes of this metric, Patient Equipment Capex is measured as the value of the patient equipment received less the net book value of dispositions of patient equipment during the accounting period.

Below, we have provided a reconciliation of EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex to our net income, the most directly comparable financial measure calculated and presented in accordance with GAAP. EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex should not be considered alternatives to net income or any other measure of financial performance calculated and presented in accordance with GAAP. Our EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex may not be comparable to similarly titled measures of other organizations because other organizations may not calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex in the same manner as we calculate these measures.

The following table reconciles net income, the most directly comparable GAAP measure, to EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex:

		Three Months Ended December 31,									Year Ended December 31,
(in thousands)		2021				2020					2021				2020
Net income		$	16,951			$	25,871				$	64,877			$	46,139
Interest (income) expense and other, net			2,787				2,215					7,533				5,810
Income tax expense			4,538				6,164					24,153				19,199
Loss from equity method investment			791				—					791				—
Depreciation and amortization			28,567				28,315					115,048				115,230
EBITDA		$	53,634			$	62,565				$	212,402			$	186,378
Strategic transformation initiatives:
Simplify(a)		$	—			$	—				$	—			$	1,159
Financial system(b)			385				432					1,466				1,846
Other initiatives(c)			23				366					137				465
Stock-based compensation one-time award at IPO(d)			606				—					4,103				—
Stock-based compensation(e)			2,221				2,910					6,046				4,839
Legal settlements(f)			—				(3,634	)				1,750				28,891
Merger and acquisition costs(g)			1,295				—					1,697				—
Offering costs(h)			283				1,454					4,434				3,280
Adjusted EBITDA		$	58,447			$	64,093				$	232,035			$	226,858
Patient Equipment Capex			(30,186	)			(29,153	)				(96,008	)			(92,635	)
Adjusted EBITDA less Patient Equipment Capex		$	28,261			$	34,940				$	136,027			$	134,223

_______________________

(a)   Simplify represents one-time advisory fees and implementation costs associated with a key 2019 business transformation initiative focused on shifting to a patient-centric platform and optimizing end-to-end customer service.
(b)   Costs associated with the implementation of a new financial system.
(c)   Other initiatives include one-time costs associated with customer service initiatives, one-time costs associated with implementation of an electronic sales, service and rental agreement, and one-time costs associated with moving the corporate headquarters in 2021.
(d)   The offering resulted in a one-time restricted stock unit (“RSUs”) grant to the Company’s Chief Financial Officer (“CFO”). The RSUs vest in tranches and are classified as liability awards since each tranche of RSUs can be settled in either cash or shares of our common stock at the CFO’s election. The first tranche of RSUs vested upon completion of the IPO and was settled in cash. The second tranche was settled in cash during the three months ended September 30, 2021. Compensation expense is recognized over the requisite service period subject to continued employment and adjusted each reporting period for changes in the fair value pro-rated for the portion of the requisite service period rendered until settlement.
(e)   Stock-based compensation has historically been granted to certain of our employees and non-employee directors in the form of profit interest units of Apria Holdings LLC, RSUs, performance-based RSUs, and stock appreciation rights (“SARs”). For time-based only RSUs and SARs, compensation expense for each separately vesting portion of the award is recognized on a straight-line basis over the vesting period for that portion of the award subject to continued service. For RSUs with performance conditions, compensation expense is recognized over the requisite service period subject to management’s estimation of the probability of vesting of such awards. Stock compensation also includes expense related to the Company’s long-term incentive plan awards which will be settled in stock.
(f)   In 2021, the amount represents the final settlement amount of a claim brought under the Private Attorneys General Act of California. In 2020, the amount represents the increase in the settlement amount in relation to a series of civil investigative demands from the United States Attorney’s Office for the Southern District of New York.
(g)   Acquisition costs include one-time costs associated with the acquisition of certain companies in 2021 and the pending merger agreement with Owens & Minor Inc. entered on January 7, 2022.
(h)   Offering costs represent one-time costs relating to public offerings. As the Company did not receive any proceeds from the offerings, these costs were expensed as incurred in selling, distribution and administrative expenses in the condensed consolidated statements of income.

Investor Contacts

Kevin Ellich
ICR Westwicke

ApriaIR@westwicke.com

Media Contacts

ApriaPR@westwicke.com 

FAQ

What were Apria's fourth quarter earnings for 2021?

Apria reported a net revenue of $296.5 million for the fourth quarter of 2021.

How did Apria's net income change in Q4 2021?

Apria's net income decreased by 34.5% to $17.0 million in the fourth quarter of 2021.

What was Apria's full year revenue for 2021?

Apria's full year revenue for 2021 was $1,145.3 million, a 3.3% increase from 2020.

What impact did supply chain constraints have on Apria in Q4 2021?

Supply chain constraints and the Philips recall slowed new patient starts in Q4 2021.

What is the outlook for Apria's product demand going forward?

Apria expects strong demand for CPAP and ventilation products to continue for the foreseeable future.